Inventor
EVARTS JERRY
US21 patents
⚠️ This page may combine multiple inventors who share the name “EVARTS JERRY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACERTA PHARMA BV
8 patentsUS9796721B2Oct 24, 2017
Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
ACERTA PHARMA BV12 citations90
US10167291B2Jan 1, 2019
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
ACERTA PHARMA BV1 citations71
US11820777B2Nov 21, 2023
Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
ACERTA PHARMA BV0 citations60
US11059829B2Jul 13, 2021
Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
ACERTA PHARMA BV0 citations60
US12448387B2Oct 21, 2025
Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
ACERTA PHARMA BV0 citations52
US12024520B2Jul 2, 2024
Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
ACERTA PHARMA BV1 citations52
US10640509B2May 5, 2020
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma
ACERTA PHARMA BV0 citations50
US10858364B2Dec 8, 2020
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
ACERTA PHARMA BV0 citations45
GILEAD CALISTOGA LLC
8 patentsUS9029384B2May 12, 2015
Phosphatidylinositol 3-kinase inhibitors
GILEAD CALISTOGA LLC10 citations83
US10059677B2Aug 28, 2018
Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof
GILEAD CALISTOGA LLC8 citations82
US10047060B2Aug 14, 2018
Process methods for phosphatidylinositol 3-kinase inhibitors
GILEAD CALISTOGA LLC7 citations82
US9567337B2Feb 14, 2017
Process methods for phosphatidylinositol 3-kinase inhibitors
GILEAD CALISTOGA LLC10 citations82
US9708327B2Jul 18, 2017
Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
GILEAD CALISTOGA LLC12 citations81
US10442805B2Oct 15, 2019
Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
GILEAD CALISTOGA LLC3 citations70
US10954199B2Mar 23, 2021
Process methods for phosphatidylinositol 3-kinase inhibitors
GILEAD CALISTOGA LLC0 citations61
US9018221B2Apr 28, 2015
Phosphatidylinositol 3-kinase inhibitors
GILEAD CALISTOGA LLC3 citations60
GILEAD SCIENCES INC
4 patentsUS9765060B2Sep 19, 2017
Phosphatidylinositol 3-kinase inhibitors
GILEAD SCIENCES INC13 citations83
US9221795B2Dec 29, 2015
Phosphatidylinositol 3-kinase inhibitors
GILEAD SCIENCES INC9 citations83
US10221197B2Mar 5, 2019
Phosphatidylinositol 3-kinase inhibitors
GILEAD SCIENCES INC2 citations72
US10308639B2Jun 4, 2019
Phosphatidylinositol 3-kinase inhibitors
GILEAD SCIENCES INC1 citations61